Casper N Bang1, Eva Gerdts2, Gerard P Aurigemma2, Kurt Boman2, Giovanni de Simone2, Björn Dahlöf2, Lars Køber2, Kristian Wachtell2, Richard B Devereux2. 1. From the Department of Medicine, Weill Cornell Medical College, New York, NY (C.N.B., G.d.S., K.W., R.B.D.); Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen, Denmark (C.N.B., L.K.); Department of Clinical Science, University of Bergen, Bergen, Norway (E.G.); Department of Medicine, Division of Cardiology, University of Massachusetts Medical School, Worcester (G.P.A.); Department of Medicine, Institution of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden (K.B.); Department of Translational Medical Sciences, Federico II University, Naples, Italy (G.d.S.); Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden (B.D.); and Department of Cardiology, Copenhagen University Hospital Glostrup, Glostrup, Denmark (K.W.). casperbang@hotmail.com. 2. From the Department of Medicine, Weill Cornell Medical College, New York, NY (C.N.B., G.d.S., K.W., R.B.D.); Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen, Denmark (C.N.B., L.K.); Department of Clinical Science, University of Bergen, Bergen, Norway (E.G.); Department of Medicine, Division of Cardiology, University of Massachusetts Medical School, Worcester (G.P.A.); Department of Medicine, Institution of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden (K.B.); Department of Translational Medical Sciences, Federico II University, Naples, Italy (G.d.S.); Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden (B.D.); and Department of Cardiology, Copenhagen University Hospital Glostrup, Glostrup, Denmark (K.W.).
Abstract
BACKGROUND:Left ventricular hypertrophy (LVH; high LV mass [LVM]) is traditionally classified as concentric or eccentric based on LV relative wall thickness. We evaluated the prediction of subsequent adverse events in a new 4-group LVH classification based on LV dilatation (high LV end-diastolic volume [EDV] index) and concentricity (mass/end-diastolic volume [M/EDV](2/3)) in hypertensive patients. METHODS AND RESULTS: In the Losartan Intervention for Endpoint Reduction (LIFE) echocardiography substudy, 939 hypertensive patients with measurable LVM at baseline were randomized to a mean of 4.8 years of losartan- or atenolol-based treatment. Patients with LVH (LVM/body surface area ≥116 and ≥96 g/m(2) in men and woman, respectively) were divided into 4 groups-concentric nondilated (increased M/EDV, normal EDV), eccentric dilated (increased EDV, normal M/EDV), concentric dilated (increased M/EDV and EDV), and eccentric nondilated (normal M/EDV and EDV)-and compared with patients with normal LVM. Time-varying LVH classes were tested for association with all-cause and cardiovascular mortality and a composite end point of myocardial infarction, stroke, heart failure, and cardiovascular death in multivariable Cox analyses. At baseline, the LVs were categorized as eccentric nondilated in 12%, eccentric dilated in 20%, concentric nondilated in 29%, concentric dilated in 14%, and normal LVM in 25%. Treatment changed the prevalence of 4 LVH groups to 23%, 4%, 5%, and 7%; 62% had normal LVM after 4 years. In time-varying Cox analyses, compared with normal LVM, those with eccentric dilated and both concentric nondilated and dilated LVH had increased risks of all-cause or cardiovascular mortality or the composite end point, whereas the eccentric nondilated group did not. CONCLUSIONS:Hypertensive patients with relatively mild LVH without either increased LV volume or concentricity have similar risk of all-cause mortality or cardiovascular events because hypertensive patients with normal LVM seem to be a low-risk group. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00338260.
RCT Entities:
BACKGROUND:Left ventricular hypertrophy (LVH; high LV mass [LVM]) is traditionally classified as concentric or eccentric based on LV relative wall thickness. We evaluated the prediction of subsequent adverse events in a new 4-group LVH classification based on LV dilatation (high LV end-diastolic volume [EDV] index) and concentricity (mass/end-diastolic volume [M/EDV](2/3)) in hypertensivepatients. METHODS AND RESULTS: In the Losartan Intervention for Endpoint Reduction (LIFE) echocardiography substudy, 939 hypertensivepatients with measurable LVM at baseline were randomized to a mean of 4.8 years of losartan- or atenolol-based treatment. Patients with LVH (LVM/body surface area ≥116 and ≥96 g/m(2) in men and woman, respectively) were divided into 4 groups-concentric nondilated (increased M/EDV, normal EDV), eccentric dilated (increased EDV, normal M/EDV), concentric dilated (increased M/EDV and EDV), and eccentric nondilated (normal M/EDV and EDV)-and compared with patients with normal LVM. Time-varying LVH classes were tested for association with all-cause and cardiovascular mortality and a composite end point of myocardial infarction, stroke, heart failure, and cardiovascular death in multivariable Cox analyses. At baseline, the LVs were categorized as eccentric nondilated in 12%, eccentric dilated in 20%, concentric nondilated in 29%, concentric dilated in 14%, and normal LVM in 25%. Treatment changed the prevalence of 4 LVH groups to 23%, 4%, 5%, and 7%; 62% had normal LVM after 4 years. In time-varying Cox analyses, compared with normal LVM, those with eccentric dilated and both concentric nondilated and dilated LVH had increased risks of all-cause or cardiovascular mortality or the composite end point, whereas the eccentric nondilated group did not. CONCLUSIONS:Hypertensivepatients with relatively mild LVH without either increased LV volume or concentricity have similar risk of all-cause mortality or cardiovascular events because hypertensivepatients with normal LVM seem to be a low-risk group. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00338260.
Authors: Sonia Garg; James A de Lemos; Colby Ayers; Michel G Khouri; Ambarish Pandey; Jarett D Berry; Ronald M Peshock; Mark H Drazner Journal: JACC Cardiovasc Imaging Date: 2015-08-19
Authors: Louise Hindsø; Andreas Fuchs; Jørgen Tobias Kühl; Emma Julia P Nilsson; Per Ejlstrup Sigvardsen; Lars Køber; Børge G Nordestgaard; Klaus Fuglsang Kofoed Journal: Int J Cardiovasc Imaging Date: 2016-11-14 Impact factor: 2.357
Authors: E Ratto; F Viazzi; D Verzola; B Bonino; A Gonnella; E L Parodi; G P Bezante; G Leoncini; R Pontremoli Journal: J Hum Hypertens Date: 2015-06-25 Impact factor: 3.012
Authors: Casper N Bang; Elsayed Z Soliman; Lara M Simpson; Barry R Davis; Richard B Devereux; Peter M Okin Journal: Am J Hypertens Date: 2017-09-01 Impact factor: 2.689
Authors: Dragan B Djordjević; Ivan S Tasić; Svetlana I Kostić; Bojana N Stamenković; Aleksandar D Djordjević; Dragan B Lović Journal: Clin Cardiol Date: 2017-12-16 Impact factor: 2.882
Authors: Chike C Nwabuo; Henrique T Moreira; Henrique D Vasconcellos; Nathan Mewton; Anders Opdahl; Kofo O Ogunyankin; Bharath Ambale-Venkatesh; Pamela J Schreiner; Anderson A C Armstrong; Cora E Lewis; David R Jacobs; Donald Lloyd-Jones; Samuel S Gidding; João A C Lima Journal: Eur Heart J Cardiovasc Imaging Date: 2019-05-01 Impact factor: 6.875